



Please type (+) inside this box →



PTO/SB/08A (10-88)  
Approved for use through 10/31/99. OMB 0551-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449A/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	10/751,056		
		Filing Date	January 2, 2004		
		First Named Inventor	Gerianne Tringali DiPiano		
		Group Art Unit	1617		
		Examiner Name	J. Kim		
Sheet	1	of	2	Attorney Docket Number	FEM 104

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
2		FENTIMAN, et al., "Dosage and duration of tamoxifen treatment for mastalgia: a controlled trial," <i>Br J Surg</i> , 75(9): 845-846 (1988).	
		FENTIMAN, et al., "Studies of tamoxifen in women with mastalgia," <i>Br. J. Clinical Prac. Sympt.</i> 68: 34-36 (1989).	
		HINTON, et al., "A double-blind controlled trial of danazol and bromocriptine in the management of severe cyclical breast pain," <i>Br. J. Clin. Practice</i> 40(8): 326-330 (1986).	
		HOLLAND & GATELEY, "Drug therapy of mastalgia. What are the options?" <i>Drugs</i> 48(5): 709-716 (1994).	
		IRVIN & MORRISON, "Effectiveness of topical non-steroidal anti-inflammatory drugs in the management of breast pain," <i>J. R. Coll. Edinb.</i> 43(3): 158-159 (1988).	
		LEONARD, et al., "Randomized, double-blind, placebo-controlled, multicenter trial of 6% miltefosine solution, a topical chemotherapy in cutaneous metastases from breast cancer," <i>J. Clin. Oncol.</i> 19: 4150-4159 (2001).	
		MANSEL & DOGLIOTTI, "European multicentre trial of bromocriptine in cyclical mastalgia," <i>Lancet</i> 335(868): 190-193 (1990).	
		MANSEL, et al., "A double blind trial of the prolactin inhibitor bromocriptine in painful benign breast disease," <i>Br. J. Surgery</i> 65(10): 724-27 (1978).	
		MANSEL, et al., "Controlled trial of the antigonadotropin danazol in painful nodular benign breast disease," <i>Lancet</i> 1(8278): 928-933 (1982).	
✓		MILLET & DIRBAS, "Clinical management of breast pain: a review," <i>Obstet. Gynecol. Survey</i> 57(7): 451-461 (2002).	

Examiner's Signature		Date Considered	3/30/07
-------------------------	--	--------------------	---------


\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents: <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Please type a plus (+) inside this box →



PTO/SB/03A (10-03)  
Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

+

<b>Substitute for form 1449A/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	10/751,056		
		Filing Date	January 2, 2004		
		First Named Inventor	Gerianne Tringali DiPiano		
		Group Art Unit			
		Examiner Name			
Sheet	2	of	2	Attorney Docket Number	FEM 104

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
2 ↓ 2		NAZLI, et al., "Controlled trial of the prolactin inhibitor bromocriptine (Parlodel) in the treatment of severe cyclical mastalgia," <i>Br J Clin Pract</i> 43: 322-327 (1989).	
		STEINBRUNN, et al., "Mastalgia. Tailoring treatment to type of breast pain," <i>Postgraduate Medicine</i> 102(5): 183-184; 187-187; 193-194 (1997).	
		TERWOGT, et al., "Phase II trial of topically applied mitofosine solution in patients with skin-metastasized breast cancer," <i>Br. J. Cancer</i> 79: 1158-1161 (1999).	
		UNGER, et al., "Hexadecylphosphocholine in the topical treatment of skin metastases in breast cancer patients," <i>Cancer Treat. Rev.</i> 17: 243-246 (1990).	

Examiner's Signature		Date Considered	7/30/07
-------------------------	--	--------------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+



+

Substitute for form 1449A/PTO

(use as many sheets as necessary)

Application Number

**10751,058**

**Filing Date**

**January 2, 2004**

**First Named Inventor**

**Gerianne DiPiano**

### Group Art Unit

1614

**Examiner Name**

Attorney Docket Number

FEM 104

Sheet

1

**of**

1

[illegible][illegible]

Date Considered
-----------------

3/30/07

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commissioner for Patent, Washington, DC 20231.**

PABST PATENT GROUP

NO. 5747 P. 6

Please type a plus sign (+) inside this box →



PTO/8201A (10-88)  
Approved for Use through 10/31/99. QMS 0031-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it carries a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it carries a valid OMB control number.			
Substitute for form 1449A/PTO		Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	10/751,058
		Filing Date	January 2, 2004
		First Named Inventor	Gerianne Tringali DiPiano
		Group Art Unit	1617
		Examiner Name	Kim, Jennifer M
		Attorney Docket Number	PEM 104
		Sheet	1

[illegible][illegible]

Examiner's Signature		Date Considered	3/30/07
-------------------------	---	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commissioner for Patent, Washington, DC 20231.**

45081024v1

FEM 104  
077049/00010

PAGE 6/6 \* RCVD AT 10/17/2005 6:25:37 PM [Eastern Daylight Time] \* SVR:USPTO-EFXRF-6/28 \* DNIS:2738300 \* CSID: \* DURATION (mm-ss):02:42